BYSI -
BeyondSpring Inc. Ordinary Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 1.78 0.15 (8.43%) |
--- |
--- |
0.0 (0.0%) |
--- |
0.15 (8.43%) |
0.0 (0.0%) |
0.0 (0.0%) |
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Earnings & Ratios
- Basic EPS:
- 0.11
- Diluted EPS:
- Basic P/E:
- 17.5455
- Diluted P/E:
- RSI(14) 1m:
- 100.0
- VWAP:
- 1.93
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
Jan 28, 2025 12:00
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Jan 28, 2025 12:00
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Nov 11, 2024 13:00
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
Sep 16, 2024 11:00
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
Sep 03, 2024 11:00
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
May 03, 2024 11:00
BeyondSpring Files 2023 Annual Report on Form 20-F
Apr 29, 2024 21:30
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
Apr 29, 2024 21:30
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
Mar 25, 2024 11:00
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Mar 06, 2024 18:54